MedPath

AI Models Show Promise in Pulmonary Embolism Diagnosis, DoximityGPT Achieves 70% Accuracy

10 months ago2 min read

Key Insights

  • A groundbreaking study at CHEST 2024 evaluated ChatGPT-3.5 and DoximityGPT for pulmonary embolism diagnosis, with DoximityGPT achieving 70% accuracy in clinical case matching.

  • The AI models demonstrated effectiveness in risk stratification and management recommendations, providing logical differential diagnoses even when initial diagnoses differed from clinical assessments.

  • Researchers from Staten Island University Hospital utilized AI models with Wells score and PESI checklist parameters, showing potential for enhanced diagnostic capabilities when CT angiography is unavailable.

In a significant advancement for artificial intelligence in healthcare diagnostics, researchers at CHEST 2024 in Boston presented compelling evidence supporting AI's potential role in diagnosing pulmonary embolism (PE). The late-breaking study, led by Dr. Zeina Morcos from Staten Island University Hospital, compared the diagnostic capabilities of two AI models against traditional clinical methods.

AI Models' Performance in Clinical Setting

The research team evaluated ChatGPT-3.5 and DoximityGPT (powered by GPT-4) using a cohort of 10 patients from the hospital's Pulmonary Embolism Response Team (PERT). The AI systems were assessed using criteria derived from the Wells score and Pulmonary Embolism Severity Index (PESI), without access to CT angiography (CTA) results.
DoximityGPT demonstrated superior performance, successfully matching clinical diagnoses in 7 out of 10 cases, while ChatGPT-3.5 achieved accuracy in 5 out of 10 cases. The higher success rate of DoximityGPT was attributed to its specialized healthcare focus, suggesting enhanced capability in clinical applications.

Clinical Decision Support and Risk Assessment

Both AI platforms showed promising capabilities beyond basic diagnosis. "Even in cases where the AI models didn't match our initial diagnosis, they offered differential diagnoses that were logical and clinically relevant," Dr. Morcos explained. The systems demonstrated proficiency in suggesting alternative conditions such as COPD exacerbation and myocardial infarction.
The AI models' ability to provide risk stratification and management recommendations aligned closely with clinician assessments, indicating potential value in supporting clinical decision-making processes, particularly in resource-constrained settings or situations requiring rapid assessment.

Future Implications and Considerations

While the results demonstrate AI's potential to enhance diagnostic capabilities, Dr. Morcos emphasized the importance of careful implementation. "As AI continues to advance, integrating seamlessly into our daily practices, we must navigate carefully," she noted, highlighting the need for rigorous evaluation and ethical considerations in AI deployment.
The study represents a significant step forward in AI-assisted healthcare, particularly for conditions like PE where rapid diagnosis can be crucial. However, the researchers maintain that AI should augment rather than replace clinical judgment, serving as a valuable tool in the healthcare provider's diagnostic arsenal.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.